Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Baihai Su
 -- 2864 2022-11-14 10:21:49 |
2 format
Jason Zhu
 Meta information modification 2864 2022-11-15 02:26:07 | |
3 format
Jason Zhu
 -1 word(s) 2863 2022-11-18 03:52:41 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Li, Y.;  Sun, P.;  Chang, K.;  Yang, M.;  Deng, N.;  Chen, S.;  Su, B. oXiris Hemofilter. Encyclopedia. Available online: https://encyclopedia.pub/entry/34466 (accessed on 27 July 2024).
Li Y,  Sun P,  Chang K,  Yang M,  Deng N,  Chen S, et al. oXiris Hemofilter. Encyclopedia. Available at: https://encyclopedia.pub/entry/34466. Accessed July 27, 2024.
Li, Yupei, Peiyan Sun, Kaixi Chang, Mei Yang, Ningyue Deng, Shanshan Chen, Baihai Su. "oXiris Hemofilter" Encyclopedia, https://encyclopedia.pub/entry/34466 (accessed July 27, 2024).
Li, Y.,  Sun, P.,  Chang, K.,  Yang, M.,  Deng, N.,  Chen, S., & Su, B. (2022, November 14). oXiris Hemofilter. In Encyclopedia. https://encyclopedia.pub/entry/34466
Li, Yupei, et al. "oXiris Hemofilter." Encyclopedia. Web. 14 November, 2022.
oXiris Hemofilter
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11226719

Critically ill patients with sepsis and severe COVID-19 are commonly characterized by a dysregulated immune response and an acute kidney injury. Continuous renal replacement therapy (CRRT) is proposed as a promising adjuvant therapy to treat these critically ill patients by removing cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns from the blood. Although multiple hemofilters, including high-cutoff membranes, the oXiris hemofilter, the CytoSorb hemoadsorption device, and the Toraymyxin hemoperfusion cartridge, have been used in clinical practice, the use of the oXiris hemofilter in critically ill patients is of particular interest because it is the only kind of hemofilter that can provide renal replacement therapy, remove endotoxins, and adsorb cytokines simultaneously. 

oXiris hemofilter critical illness acute kidney injury

1. Introduction

Critical illnesses, including sepsis and severe COVID-19, are commonly characterized by a dysregulated immune response and multiple organ dysfunction, such as acute respiratory distress syndrome, acute kidney injuries (AKIs), and neurological dysfunctions, and are associated with high morbidity and mortality . Beyond conventional antibiotic therapy and fluid resuscitation therapy, continuous renal replacement therapy (CRRT) has also been widely used in intensive care units (ICU) to provide renal support and to modulate the dysregulated immune response for patients with AKIs and immune dysfunctions worldwide . Traditional CRRT mainly removes solutes and water to maintain hemostasis through diffusion and convection mechanisms using semipermeable hemofilters [1]. However, contemporary CRRT is also proposed as a promising therapy to remove proinflammatory cytokines, pathogen-associated molecular patterns, and damage-associated molecular patterns through the adsorption mechanism in ICU settings [2]. In fact, the solute removal spectrum of a specific hemofilter is significantly dependent on its own membrane/adsorbent structure and treatment dose. In the current clinical practice, multiple hemofilters, including high-cutoff membranes, the oXiris membrane, the CytoSorb hemoadsorption device, and Toraymyxin hemoperfusion cartridges, are used to treat critically ill patients [3]. Among them, the oXiris hemofilter, a high-permeability polyacrylonitrile-based membrane (polyacrylonitrile: AN69), is the only kind of hemofilter that can provide renal replacement therapy, remove endotoxin molecules, and adsorb cytokines simultaneously [4]. Although two previous publications generally discussed the use of oXiris and other hemofilters in patients with sepsis or COVID-19, respectively [5][6], they unfortunately failed to address the safety concerns when delivering the oXiris-CRRT sessions. With the increasing use of oXiris-CRRT in both septic and severe COVID-19 patients during the COVID-19 pandemic, it has become available and important to summarize the latest clinical evidence to investigate the efficacy and safety of oXiris-CRRT in critically ill patients through an updated narrative review that exclusively focuses on the oXiris hemofilter.

2. History of the oXiris Hemofilter

The oXiris hemofilter (Baxter, Meyzieu, France) employs a positively-charged polyethyleneimine (PEI) coating on an AN69 membrane to achieve simultaneous cytokine adsorption and endotoxin removal from the bloodstream [7]. The conventional AN69 membrane is made of a copolymer of acrylonitrile and sodium methallyl sulfonate, which significantly eliminate cytokines through the negatively-charged sulfonate groups in their bulk area [8]. However, AN69 membranes can interact with the blood to cause bradykinin generation and subsequent anaphylactic reactions in patients being dialyzed with AN69 membranes [9]. In this regard, an AN69 surface-treated (AN69ST) membrane with a PEI coating was developed to improve hemocompatibility by neutralizing the negative charges of conventional AN69 membranes. The PEI layer of the AN69ST membrane can also adsorb heparin to allow heparin priming before use [10]. The oXiris hemofilter further advances the AN69ST membrane by grafting more PEI molecules onto the AN69ST membrane surface to increase the binding of negatively-charged endotoxins with the PEI layer [11]. The oXiris hemofilter is now the only hemofilter that can provide renal replacement therapy, remove endotoxin molecules, and adsorb cytokines simultaneously. Currently, the oXiris hemofilter is available for stand-alone use with different CRRT modalities, such as continuous venovenous hemofiltration, hemodiafiltration, or hemodialysis, via the PrismaFlex and PrisMax systems (Baxter, Deerfield, IL, USA).

3. Clinical Use of the oXiris Hemofilter in Sepsis

3.1. Rationale

Sepsis, the leading cause of AKIs in critically ill patients, is defined as a dysregulated host response secondary to infection [12][13]. Sepsis has become a major healthcare concern with considerable global economic consequences due to its high incidence and mortality rate for almost four decades [14]. During sepsis, dysregulated immune activation occurs after endotoxins are recognized by pattern-recognition receptors [15]. This signal can further activate leukocytes and induce the production and release of both pro- and anti-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), IL-6, IL-8, and IL-10. The release of these cytokines into the bloodstream is termed a “cytokine storm”, which further contributes to cellular injury, catabolism, and multiple organ dysfunction [4][16]. In fact, high endotoxin and cytokine levels are associated with multiple organ failure and a high mortality rate in sepsis [17]. Therefore, the removal of endotoxins and cytokines by oXiris-CRRT may have benefits for septic patients with an AKI [13][16].

3.2. Preclinical Studies

Rimmelé et al. first compared the effect of the oXiris hemofilter with the AN69 hemofilter on the adsorption kinetics of both endotoxins and cytokines in vitro and in vivo [18]. Under in vitro conditions, 500 mL of bovine serum spiked with 40 EU/mL lipopolysaccharides was circulated in a closed extracorporeal circuit in contact with the oXiris membranes at a flow rate of 250 mL/min. Then, the serum samples were withheld at 0, 10, 30, and 60 min to investigate the adsorption kinetic profile of endotoxins and cytokines using the oXiris hemofilter. The results showed that 66% of endotoxins were adsorbed by the oXiris hemofilter after the 60 min in vitro hemofiltration experiment, while the AN69 hemofilter had little effect on endotoxin removal. Meanwhile, the oXiris hemofilter also showed a greater cytokine adsorption capacity than the AN69 hemofilter. In a porcine sepsis model induced by live Pseudomonas aeruginosa, the authors further demonstrated that CRRT with the oXiris hemofilter significantly improved hemodynamics, as evidenced by lower fluid requirements, lactate levels, and pulmonary arterial hypertension compared to the AN69 hemofilter. Additionally, a significant decrease in the endotoxin level after 1 h of hemofiltration was observed in the oXiris group [18]. More recently, another in vitro study by Malard et al. compared the adsorption efficiency of inflammatory mediators and endotoxins of the oXiris hemofilter (Baxter, Meyzieu, France), the CytoSorb hemofilter (CytoSorbents Corporation, New Jersey, USA), and the Toraymyxin hemofilter (Toray Industries, Tokyo, Japan) [19]. Heparinized human plasma was preincubated with pathological quantities of inflammatory cytokines or endotoxins and then filtered in a closed-loop circulation model for 2 h. The results showed that there was no significant difference in the endotoxin removal rates between the oXiris hemofilter (68.0 ± 4.4%) and the Toraymyxin hemofilter (83.4 ± 3.8%) at 120 min, and the oXiris hemofilter displayed an adsorption efficiency similar to the CytoSorb hemofilter for the removal of most cytokines [19]. Specifically, the total endotoxin adsorption amount over 6 h with oXiris was 6.9 vs. 9.7 μg for Toraymyxin. Considering that the endotoxin plasma load in the blood of septic patients was previously reported to be in the range of 3–30 μg [20], these results supported the clinically relevant endotoxin removal capacities of the oXiris® hemofilter.

3.3. Clinical Studies

Encouraging results from in vitro studies have significantly increased the clinical use of the oXiris® hemofilter in septic patients in Europe and the Asia–Pacific region. In a randomized crossover double-blind study enrolling 16 sepsis-associated AKI patients who had an endotoxin level higher than 0.03 EU/mL, Broman et al. found that CRRT with the oXiris hemofilter was associated with a greater removal of endotoxins and cytokines (namely, TNF-α, IL-6, IL-8, and IFN-γ) than that with a standard AN69ST hemofilter (Baxter, Meyzieu, France) [11]. Notably, endotoxin levels decreased during the CRRT treatment in seven of nine (77.8%) patients in the oXiris group but only in one of six (16.7%) patients in the AN69ST group, suggesting that oXiris-CRRT can effectively eliminate endotoxins and cytokines from the bloodstream of septic patients in real clinical practices.
Dating back to 2013, Shum et al. first conducted a retrospective case-series study to determine whether the use of the oXiris hemofilter improved organ dysfunction in patients with severe Gram-negative bacterial infections. A total of 30 patients with sepsis-associated AKIs who received one oXiris-CRRT session were recruited [21]. The results showed that the SOFA score was significantly reduced by 37% at 48 h post-initiation of CRRT with the oXiris hemofilter versus an increment of 3% in the historical controls that received CRRT with a polysulfone hemofilter. Meanwhile, there were no significant differences in the ICU and in-hospital mortality rates between the two groups. Subsequently, a growing number of small-size clinical studies collectively found that CRRT with the oXiris hemofilter could improve hemodynamics and decrease the cytokines, procalcitonin, endotoxins, and SOFA scores in septic patients with AKIs [22][23][24][25][26][27]. Additionally, Schwindenhammer et al. found that oXiris-CRRT was associated with a higher observed survival than was predicted by the SAPS II score in patients with septic shock in two French centers [28].
Most recently, the conflicting results of several cohort studies that compared the effects of oXiris vs. AN69ST hemofilters on cytokine levels and clinical outcomes in Chinese septic patients have become available. Zang et al. found that patients receiving oXiris-CRRT had a more remarkable improvement in hemodynamics and had lower cytokine concentrations than those receiving AN69ST-CRRT, but there were no significant differences in clinical outcomes, such as the in-hospital mortality rate, intensive care unit length of stay (LOS), and hospital LOS [29]. In another retrospective observational study enrolling 136 patients with sepsis and AKIs, Guan et al. reported a significantly lower 7-day (47.1% vs. 74.2%) and 14-day mortality rate in the oXiris group than in the AN69ST group (58.5% vs. 80.3%), although the difference in the 90-day mortality rate (71.4% vs. 81.8%) was insignificant [4]. Compared with AN69ST-CRRT, oXiris-CRRT was also associated with a faster reduction in the SOFA score and a greater decrease in the procalcitonin level and vasoactive-inotropic score. Furthermore, the authors found that oXiris-CRRT was associated with a lower risk of death with a hazard ratio of 0.500 (95% CI: 0.280–0.892; p = 0.019) than AN69ST using a multivariate Cox regression model. Likewise, Xie et al. performed an inverse probability on the treatment-weighted analysis to compare the effect of oXiris-CRRT vs. ANS6ST-CRRT on patient-centered clinical outcomes, including the 28-day mortality rate, the 72 h lactate level, and the need for norepinephrine [30]. Their results showed that oXiris-CRRT was associated with a lower 28-day mortality rate (47.3% vs. 73.3%) and reduced lactate levels, norepinephrine doses, and procalcitonin in septic shock patients vs. AN69ST-CRRT. It is also noteworthy that these conflicting results should be interpreted with caution because of the inherent limitations of cohort studies, such as selection bias and small sample size. In fact, the mortality rate of septic patients in the oXiris group remained high (in a range of 40.9% to 71.4%) [4][29][30], suggesting that oXiris-CRRT was usually used as a remedial treatment in the practice at that time. Therefore, further studies should be performed to investigate whether the early initiation of oXiris-CRRT may be beneficial in the reduction of in-hospital mortality rates in patients with sepsis-associated AKIs. Meanwhile, it is also important to identify whether the oXiris hemofilter could reduce the mortality rate vs. the standard of care and other hemofilters, such as the Cytosorb hemofilter and the Toraymyxin hemoperfusion cartridge.
Although there have been a handful of encouraging clinical studies as mentioned above, the absence of high-quality studies and clinical guidelines makes the wide use of oXiris not yet advocated, leading to variability in clinical practice. Currently, the delivery of oXiris-CRRT is mainly based on consensus recommendations from Europe and the Asian–Pacific region [7][31]. First, the initiation of oXiris-CRRT is recommended when patients develop both an AKI and septic shock. The decision to initiate oXiris-CRRT is usually driven by a clinical judgment based on a combination of clinical signs, such as hemodynamic instability; microcirculatory dysfunction; MODS; and laboratory parameters, such as elevated serum levels of procalcitonin, IL-6, and lactate [7]. However, the setting of AKIs pertains to patient selection, and the optimal circumstances for CRRT initiation remain one of the most controversial and clinically uncertain aspects of CRRT delivery. The initiation of dialysis early versus delayed in the intensive care unit (IDEAL-ICU) trial in 2018 that enrolled 488 patients with severe AKIs due to septic shock and with no urgent indications for RRT initiation found that early RRT initiation, as compared to delaying RRT initiation by 48 h, did not reduce the 90-day mortality rate [32]. Likewise, in 2020, the multinational standard versus accelerated renal replacement therapy in acute kidney injury trial also showed that early RRT initiation did not improve the primary outcome of the 90-day all-cause mortality rate, but it increased the likelihood of persistent RRT dependence at 90 days after randomization. Second, the oXiris hemofilter is recommended to be changed at 12 to 24 h post-initiation if patients have persistently high cytokine levels or if premature circuit clotting is anticipated. However, the filter lifespan may be up to 72 h if patients show remarkable improvements in clinical signs and laboratory parameters after oXiris-CRRT [7]. Third, a therapeutic effect evaluation should be performed at 24 h post-initiation of oXiris-CRRT to determine whether the oXiris treatment succeeded or failed based on clinical observations and laboratory markers. Fourth, the CRRT prescriptions for the oXiris hemofilters do not differ significantly from other conventional hemofilters. Regional citrate anticoagulation (RCA) or systemic heparin anticoagulation is recommended. As for CRRT intensity, the landmark VA-NIH ATN and RENAL trials collectively demonstrated that intensive small-solute clearance was not superior to less-intensive clearance [33][34]. Accordingly, an effluent flow of 20–25 mL/kg/h has become the standard of care for the delivery of CRRT [1]. Likewise, the consensus recommendations recommend that the target dose of an oXiris-CRRT session should reach 20 to 35 mL/kg/h with a blood flow rate of 150 to 200 mL/min [7]. Of note, the key questions in delivering oXiris-CRRT remain uncovered, such as the timing of initiation and weaning, recommended therapeutic dose, optimal duration of use, indication of filter exchange, and definition of treatment success, which, unfortunately, limits the wide use of the oXiris hemofilter. Moreover, despite currently having insufficient information to generate a comprehensive cost-effectiveness analysis of oXiris-CRRT, a recent retrospective study found that the cost of oXiris-CRRT is about two times more than that of AN69ST-CRRT, with an average cost of 1800 dollars per filter. Therefore, the use of oXiris in low-income countries may be hindered by its high cost, the limited availability and reliability of endotoxin detection experiments, and restricted access to oXiris. High-quality RCTs or prospective randomized crossover studies are desperately needed for better clinical decisions.

4. Clinical Use of the oXiris Hemofilter in COVID-19

4.1. Rationale

Multiple studies have reported that cytokine storms, characterized by highly elevated levels of proinflammatory cytokines such as interleukin-6 (IL-6), IL-1β, IL-18, and granulocyte–macrophage colony-stimulating factor, and immunothrombosis are associated with the disease severities and clinical outcomes of critically ill COVID-19 patients [35]. Recently, cytokine storms have been proposed to crosstalk with immunothrombosis and endothelial dysfunctions to mediate thrombotic events, multiple organ dysfunctions, and death in COVID-19 patients [36]. A recent meta-analysis identified an overall estimated pooled incidence of venous thromboembolisms of 17.0 % in hospitalized patients with COVID-19 [37]. Beyond thromboembolisms, AKIs are another common complication of severe COVID-19, with up to 45% of COVID-19 patients in the ICU setting requiring RRT [36]. The pathophysiology of COVID-19 AKIs is thought to involve local and systemic inflammatory and immune responses, endothelial injuries, the activation of coagulation pathways and the renin–angiotensin system, ischemic acute tubular necrosis, and the direct viral invasion of renal proximal tubular cells and podocytes [36][38]. In a multicenter cohort study of 3099 critically ill adults with COVID-19 across the USA, Gupta et al. found that AKIs treated with kidney replacement therapy (AKI-RRT) were associated with a hospital mortality rate of >60% and that patient-level risk factors for AKI-RRT included chronic kidney disease, male gender, non-White race, hypertension, diabetes mellitus, being overweight, a higher d-dimer, and a greater severity of hypoxemia on ICU admission [38]. Owing to its capacity to adsorb proinflammatory mediators from the bloodstream during CRRT sessions, the oXiris hemofilter was authorized for emergency use to overcome AKIs and/or cytokine storms in adults with COVID-19 by the FDA in April 2020.

4.2. Clinical Evidence

Early small-size case series collectively found that CRRT with the oXiris hemofilter significantly decreased proinflammatory cytokine levels and improved hemodynamics and organ function in critically ill COVID-19 patients [39][40][41][42][43][44]. Compared to the mortality rates calculated by the acute physiology and chronic health evaluation IV score, the mean observed mortality rates were lower after oXiris-CRRT treatment [42][44]. Premužić et al. also demonstrated that critically ill COVID-19 patients receiving the oXiris treatment survived significantly longer than other ICU COVID-19 patients [42]. In contrast, another single-center study reported negative results for removing circulating cytokines and inflammatory chemokines in non-AKI patients with severe COVID-19, which might be attributed to the relatively lower concentration of IL-6 in COVID-19 patients than in patients with septic shock [45]. Furthermore, the differences in inflammatory subphenotypes, the SARS-CoV-2 viral burden, and comorbidities may also have an impact on the production and release of circulating cytokines and chemokines [45].
Currently, there is an ongoing open-label RCT (oXAKI-COV study) comparing CRRT with the oXiris membrane vs. the standard AN69 membrane during a 72 h treatment period in critically ill COVID-19 patients with AKIs (NCT04597034). The primary outcome of the oXAKI-COV study was the change in the norepinephrine requirement by at least 0.1 mg/kg/min to maintain a similar mean arterial pressure after the initiation of CRRT. Secondary outcome measures included the change in serum IL-6, IL-10, and TNF-α levels and the change in the length of ICU stays in these patients. It is believed that the final analysis of such a high-quality RCT could provide solid evidence for better clinical decisions.

References

  1. Monard, C.; Abraham, P.; Schneider, A.; Rimmelé, T. New Targets for Extracorporeal Blood Purification Therapies in Sepsis. Blood Purif. 2022, in press.
  2. Ricci, Z.; Romagnoli, S.; Reis, T.; Bellomo, R.; Ronco, C. Hemoperfusion in the intensive care unit. Intensive Care Med. 2022, 48, 1397–1408.
  3. Guan, M.; Wang, H.; Tang, X.; Zhao, Y.; Wang, F.; Zhang, L.; Fu, P. Continuous Renal Replacement Therapy With Adsorbing Filter oXiris in Acute Kidney Injury With Septic Shock: A Retrospective Observational Study. Front. Med. 2022, 9, 789623.
  4. Niazi, N.S.; Nassar, T.I.; Stewart, I.J.; Honore, P.M.; Sharma, K.; Chung, K.K. A Review of Extracorporeal Blood Purification Techniques for the Treatment of Critically Ill Coronavirus Disease 2019 Patients. ASAIO J. 2022, 68, 1219–1227.
  5. Hellman, T.; Uusalo, P.; Järvisalo, M.J. Renal Replacement Techniques in Septic Shock. Int. J. Mol. Sci. 2021, 22, 10238.
  6. Zhang, L.; Cove, M.; Nguyen, B.G.; Lumlertgul, N.; Ganesh, K.; Chan, A.; Bui, G.T.H.; Guo, C.; Li, J.; Liu, S.; et al. Adsorptive hemofiltration for sepsis management: Expert recommendations based on the Asia Pacific experience. Chin. Med. J. 2021, 134, 2258–2260.
  7. Lee, K.H.; Ou, S.M.; Tsai, M.T.; Tseng, W.C.; Yang, C.Y.; Lin, Y.P.; Tarng, D.C. AN69 Filter Membranes with High Ultrafiltration Rates during Continuous Venovenous Hemofiltration Reduce Mortality in Patients with Sepsis-Induced Multiorgan Dysfunction Syndrome. Membranes 2021, 11, 837.
  8. Verresen, L.; Fink, E.; Lemke, H.D.; Vanrenterghem, Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int. 1994, 45, 1497–1503.
  9. Guéry, B.; Alberti, C.; Servais, A.; Harrami, E.; Bererhi, L.; Zins, B.; Touam, M.; Joly, D. Hemodialysis without systemic anticoagulation: A prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS ONE 2014, 9, e97187.
  10. Broman, M.E.; Hansson, F.; Vincent, J.L.; Bodelsson, M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: A randomized crossover double-blind study. PLoS ONE 2019, 14, e0220444.
  11. Peerapornratana, S.; Manrique-Caballero, C.L.; Gómez, H.; Kellum, J.A. Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019, 96, 1083–1099.
  12. Bellomo, R.; Kellum, J.A.; Ronco, C.; Wald, R.; Martensson, J.; Maiden, M.; Bagshaw, S.M.; Glassford, N.J.; Lankadeva, Y.; Vaara, S.T.; et al. Acute kidney injury in sepsis. Intensive Care Med. 2017, 43, 816–828.
  13. Cecconi, M.; Evans, L.; Levy, M.; Rhodes, A. Sepsis and septic shock. Lancet 2018, 392, 75–87.
  14. Boyd, J.H.; Russell, J.A.; Fjell, C.D. The meta-genome of sepsis: Host genetics, pathogens and the acute immune response. J. Innate Immun. 2014, 6, 272–283.
  15. Yang, Q.; Li, Y.; Tuohuti, P.; Qin, Z.; Zhang, Z.; Zhao, W.; Su, B. Advances in the Development of Biomaterials for Endotoxin Adsorption in Sepsis. Front. Bioeng. Biotechnol. 2021, 9, 699418.
  16. Klein, D.J.; Derzko, A.; Foster, D.; Seely, A.J.; Brunet, F.; Romaschin, A.D.; Marshall, J.C. Daily variation in endotoxin levels is associated with increased organ failure in critically ill patients. Shock 2007, 28, 524–529.
  17. Rimmelé, T.; Assadi, A.; Cattenoz, M.; Desebbe, O.; Lambert, C.; Boselli, E.; Goudable, J.; Etienne, J.; Chassard, D.; Bricca, G.; et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol. Dial. Transplant. 2009, 24, 421–427.
  18. Malard, B.; Lambert, C.; Kellum, J.A. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med. Exp. 2018, 6, 12.
  19. Romaschin, A.D.; Obiezu-Forster, C.V.; Shoji, H.; Klein, D.J. Novel Insights into the Direct Removal of Endotoxin by Polymyxin B Hemoperfusion. Blood Purif. 2017, 44, 193–197.
  20. Shum, H.P.; Chan, K.C.; Kwan, M.C.; Yan, W.W. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection. Hong Kong Med. J. Xianggang Yi Xue Za Zhi 2013, 19, 491–497.
  21. Turani, F.; Barchetta, R.; Falco, M.; Busatti, S.; Weltert, L. Continuous Renal Replacement Therapy with the Adsorbing Filter oXiris in Septic Patients: A Case Series. Blood Purif. 2019, 47 (Suppl. 3), 54–58.
  22. Lumlertgul, N.; Srisawat, N. The haemodynamic effects of oXiris haemofilter in septic shock patients requiring renal support: A single-centre experience. Int. J. Artif. Organs 2021, 44, 17–24.
  23. Zhai, Y.; Pan, J.; Zhang, C. The application value of oXiris-endotoxin adsorption in sepsis. Am. J. Transl. Res. 2021, 13, 3839–3844.
  24. Feng, J.; Zhang, S.; Ai, T.; Wang, L.; Gao, Y.; Li, W.; Zhu, M. Effect of CRRT with oXiris filter on hemodynamic instability in surgical septic shock with AKI: A pilot randomized controlled trial. Int. J. Artif. Organs 2022, 45, 801–808.
  25. Zhang, L.; Tang, G.K.Y.; Liu, S.; Cai, J.; Chan, W.M.; Yang, Y.; Chang, P.; Wei, T.; Liu, X.; Yao, Q.; et al. Hemofilter with Adsorptive Capacities: Case Report Series. Blood Purif. 2019, 47, 45–50.
  26. Zhou, Y.; Wu, C.; Ouyang, L.; Peng, Y.; Zhong, D.; Xiang, X.; Li, J. Application of oXiris-continuous hemofiltration adsorption in patients with sepsis and septic shock: A single-centre experience in China. Front. Public Health 2022, 10, 1012998.
  27. Schwindenhammer, V.; Girardot, T.; Chaulier, K.; Grégoire, A.; Monard, C.; Huriaux, L.; Illinger, J.; Leray, V.; Uberti, T.; Crozon-Clauzel, J.; et al. oXiris® Use in Septic Shock: Experience of Two French Centres. Blood Purif. 2019, 47 (Suppl. 3), 28–35.
  28. Zang, S.; Chen, Q.; Zhang, Y.; Xu, L.; Chen, J. Comparison of the Clinical Effectiveness of AN69-oXiris versus AN69-ST Filter in Septic Patients: A Single-Centre Study. Blood Purif. 2022, 51, 617–629.
  29. Xie, J.; Xiao, W.; Lin, J. Effect of oXiris-CVVH on the Clinical Outcomes of Patients with Septic Shock: An Inverse Probability of Treatment-Weighted Analysis. Blood Purif. 2022, in press.
  30. Pickkers, P.; Vassiliou, T.; Liguts, V.; Prato, F.; Tissieres, P.; Kloesel, S.; Turani, F.; Popevski, D.; Broman, M.; Gindac, C.M.; et al. Sepsis Management with a Blood Purification Membrane: European Experience. Blood Purif. 2019, 47 (Suppl. 3), 36–44.
  31. Barbar, S.D.; Clere-Jehl, R.; Bourredjem, A.; Hernu, R.; Montini, F.; Bruyère, R.; Lebert, C.; Bohé, J.; Badie, J.; Eraldi, J.P.; et al. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N. Engl. J. Med. 2018, 379, 1431–1442.
  32. Palevsky, P.M.; Zhang, J.H.; O’Connor, T.Z.; Chertow, G.M.; Crowley, S.T.; Choudhury, D.; Finkel, K.; Kellum, J.A.; Paganini, E.; Schein, R.M.; et al. Intensity of renal support in critically ill patients with acute kidney injury. N. Engl. J. Med. 2008, 359, 7–20.
  33. Bellomo, R.; Cass, A.; Cole, L.; Finfer, S.; Gallagher, M.; Lo, S.; McArthur, C.; McGuinness, S.; Myburgh, J.; Norton, R.; et al. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 2009, 361, 1627–1638.
  34. Yang, L.; Xie, X.; Tu, Z.; Fu, J.; Xu, D.; Zhou, Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct. Target. Ther. 2021, 6, 255.
  35. Legrand, M.; Bell, S.; Forni, L.; Joannidis, M.; Koyner, J.L.; Liu, K.; Cantaluppi, V. Pathophysiology of COVID-19-associated acute kidney injury. Nat. Rev. Nephrol. 2021, 17, 751–764.
  36. Jiménez, D.; García-Sanchez, A.; Rali, P.; Muriel, A.; Bikdeli, B.; Ruiz-Artacho, P.; Le Mao, R.; Rodríguez, C.; Hunt, B.J.; Monreal, M. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021, 159, 1182–1196.
  37. Gupta, S.; Coca, S.G.; Chan, L.; Melamed, M.L.; Brenner, S.K.; Hayek, S.S.; Sutherland, A.; Puri, S.; Srivastava, A.; Leonberg-Yoo, A.; et al. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J. Am. Soc. Nephrol. JASN 2021, 32, 161–176.
  38. Padala, S.A.; Vakiti, A.; White, J.J.; Mulloy, L.; Mohammed, A. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA. J. Clin. Med. Res. 2020, 12, 454–457.
  39. Zhang, H.; Zhu, G.; Yan, L.; Lu, Y.; Fang, Q.; Shao, F. The absorbing filter Oxiris in severe coronavirus disease 2019 patients: A case series. Artif. Organs 2020, 44, 1296–1302.
  40. Rosalia, R.A.; Ugurov, P.; Neziri, D.; Despotovska, S.; Kostoska, E.; Veljanovska-Kiridjievska, L.; Kuzmanov, D.; Trifunovski, A.; Popevski, D.; Villa, G.; et al. Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study. Blood Purif. 2022, 51, 233–242.
  41. Premužić, V.; Babel, J.; Gardijan, D.; Lapić, I.; Gabelica, R.; Ostojić, Z.; Lozić, M.; Pavliša, G.; Hrabak, M.; Knežević, J.; et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients. Ther. Apher. Dial. 2022, 26, 316–329.
  42. Ugurov, P.; Popevski, D.; Gramosli, T.; Neziri, D.; Vuckova, D.; Gjorgon, M.; Stoicovski, E.; Marinkovic, S.; Veljanovska-Kiridjievska, L.; Ignevska, K.; et al. Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris(®)) Hemofilter as a Treatment Modality for COVID-19 Patients: A Single-Centre Case Series. Braz. J. Cardiovasc. Surg. 2022, 37, 35–47.
  43. Villa, G.; Romagnoli, S.; De Rosa, S.; Greco, M.; Resta, M.; Pomarè Montin, D.; Prato, F.; Patera, F.; Ferrari, F.; Rotondo, G.; et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: A pilot study. Crit. Care 2020, 24, 605.
  44. Kang, K.; Luo, Y.; Gao, Y.; Zhang, J.; Wang, C.; Fei, D.; Yang, W.; Meng, X.; Ye, M.; Gao, Y.; et al. Continuous Renal Replacement Therapy With oXiris Filter May Not be an Effective Resolution to Alleviate Cytokine Release Syndrome in Non-AKI Patients With Severe and Critical COVID-19. Front. Pharmacol. 2022, 13, 817793.
  45. Vega, O. A Randomized, Controlled Rrial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 oXiris) in Comparison with a Semi-Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study. Available online: https://clinicaltrials.gov/ct2/show/NCT04597034 (accessed on 9 September 2022).
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Health Care Sciences & Services
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Yupei Li
,
Peiyan Sun
,
Kaixi Chang
,
Mei Yang
,
Ningyue Deng
,
Shanshan Chen
,
Baihai Su
View Times: 592
Revisions: 3 times (View History)
Update Date: 18 Nov 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback